百花医药 (600721.SH) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	358.6M	388.3M	385.8M	369.3M	349.9M
Cost of Revenue	199.4M	211.5M	188.3M	188.2M	210.2M
Gross Profit	159.2M	176.8M	197.5M	181.1M	139.7M
Operating Expenses
R&D Expense	22.2M	24.4M	29.5M	31.9M	27.5M
SG&A Expense	—	—	—	—	—
General & Admin Expense	58.4M	58.5M	60.0M	63.6M	65.8M
Selling & Marketing Expense	11.6M	12.0M	11.4M	13.1M	15.4M
Other Expenses	—	—	—	—	—
Total Operating Expenses	96.8M	99.0M	104.8M	113.0M	113.3M
Cost and Expenses	296.1M	310.5M	293.1M	301.2M	323.5M
Operating Income (EBIT)	29.6M	44.2M	37.0M	18.0M	(30.7M)
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	29.5M	44.2M	36.9M	16.5M	(32.1M)
Income Tax Expense	2.9M	3.5M	(4.6M)	3.5M	2.6M
Bottom Line
Net Income	26.6M	40.7M	41.5M	13.0M	(34.8M)
Earnings from Cont. Ops	26.6M	40.7M	41.5M	13.0M	(34.7M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	26.6M	40.7M	41.5M	13.0M	(34.8M)
Per Share
Basic EPS	CN¥0.07	CN¥0.11	CN¥0.11	CN¥0.03	(CN¥0.09)
Diluted EPS	CN¥0.07	CN¥0.11	CN¥0.11	CN¥0.03	(CN¥0.09)
Revenue Per Share	CN¥0.93	CN¥1.01	CN¥1.01	CN¥0.97	CN¥0.93
Shares
Basic Shares Outstanding	384.0M	384.2M	382.3M	379.3M	375.8M
Diluted Shares Outstanding	384.0M	384.2M	382.3M	379.3M	375.8M
Profitability Metrics
EBITDA	—	63.9M	56.6M	41.1M	(3.2M)
D&A	—	19.6M	19.6M	23.2M	27.6M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026